{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:54:27Z","timestamp":1790488467404,"version":"4.1.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.lfs.2021.119635","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T11:17:54Z","timestamp":1621250274000},"page":"119635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Diabetic nephropathy: A twisted thread to unravel"],"prefix":"10.1016","volume":"278","author":[{"given":"Neha","family":"Dagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamelika","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Taraphdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravichandiran","family":"Velayutham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somasundaram","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2021.119635_bb0005","first-page":"S81","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0010","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.2337\/diacare.28.9.2130","article-title":"The burden of mortality attributable to diabetes: realistic estimates for the year 2000","volume":"28","author":"Roglic","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0015","series-title":"International Diabetes Federation. IDF Diabetes Atlas","author":"Aguiree","year":"2013"},{"key":"10.1016\/j.lfs.2021.119635_bb0020","doi-asserted-by":"crossref","unstructured":"Y. Shi, F.B. Hu, The global implications of diabetes and cancer., Lancet (London, England). 383 (2014) 1947\u20131948.","DOI":"10.1016\/S0140-6736(14)60886-2"},{"key":"10.1016\/j.lfs.2021.119635_bb0025","doi-asserted-by":"crossref","unstructured":"S. Yamagishi, K. Fukami, S. Ueda, S. Okuda, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention, Curr. Drug Targets 8 (2007) 952\u2013959.","DOI":"10.2174\/138945007781386884"},{"key":"10.1016\/j.lfs.2021.119635_bb0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10557-017-6755-9","article-title":"Diabetic nephropathy: a tangled web to unweave","volume":"31","author":"Magee","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.lfs.2021.119635_bb0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMcp011773","article-title":"Nephropathy in patients with type 2 diabetes","volume":"346","author":"Remuzzi","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0040","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/JOE-14-0437","article-title":"Autophagy in diabetic nephropathy","volume":"224","author":"Ding","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.lfs.2021.119635_bb0045","doi-asserted-by":"crossref","unstructured":"K.M. Thrailkill, R.C. Bunn, J.L. Fowlkes, Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy, Endocrine. 35 (2009) 1\u201310.","DOI":"10.1007\/s12020-008-9114-6"},{"key":"10.1016\/j.lfs.2021.119635_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4239\/wjd.v5.i3.393","article-title":"Diabetic nephropathy and inflammation","volume":"5","author":"Duran-Salgado","year":"2014","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.lfs.2021.119635_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl. Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/CS20120198","article-title":"Inflammation and the pathogenesis of diabetic nephropathy","volume":"124","author":"Wada","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.lfs.2021.119635_bb0065","doi-asserted-by":"crossref","unstructured":"L. Huang, R. Khardori, Pathogenesis of diabetic nephropathy, in: Manag. Diabet. Nephropathies Clin. Pract., Springer, 2017: pp. 23\u201345.","DOI":"10.1007\/978-3-319-08873-0_2"},{"key":"10.1016\/j.lfs.2021.119635_bb0070","doi-asserted-by":"crossref","unstructured":"A.K.H. Lim, Diabetic nephropathy\u2013complications and treatment, Int. J. Nephrol. Renov. Dis. 7 (2014) 361.","DOI":"10.2147\/IJNRD.S40172"},{"key":"10.1016\/j.lfs.2021.119635_bb0075","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ncpendmet0894","article-title":"The pathogenesis of diabetic nephropathy","volume":"4","author":"Dronavalli","year":"2008","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2021.119635_bb0080","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1055\/s-2001-18600","article-title":"Pathogenesis of diabetic nephropathy","volume":"109","author":"Raptis","year":"2001","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.lfs.2021.119635_bb0085","doi-asserted-by":"crossref","unstructured":"K. Shikata, H. Makino, Role of macrophages in the pathogenesis of diabetic nephropathy, Contrib. Nephrol. 134 (2001) 46\u201354.","DOI":"10.1159\/000060147"},{"key":"10.1016\/j.lfs.2021.119635_bb0090","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2021.119635_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.diabet.2009.05.007","article-title":"DNA damage and plasma antioxidant indices in Bangladeshi type 2 diabetic patients","volume":"36","author":"Arif","year":"2010","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.lfs.2021.119635_bb0100","doi-asserted-by":"crossref","unstructured":"E. Tatsch, G. V Bochi, S.J. Piva, J.A.M. De Carvalho, H. Kober, V.D. Torbitz, T. Duarte, C. Signor, A.C. Coelho, M.M.M.F. Duarte, Association between DNA strand breakage and oxidative, inflammatory and endothelial biomarkers in type 2 diabetes, Mutat. Res. Mol. Mech. Mutagen. 732 (2012) 16\u201320.","DOI":"10.1016\/j.mrfmmm.2012.01.004"},{"key":"10.1016\/j.lfs.2021.119635_bb0105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00125-002-0831-8","article-title":"Urinary excretion of 8-oxo-7, 8-dihydro-2\u2032-deoxyguanosine as a predictor of the development of diabetic nephropathy","volume":"45","author":"Hinokio","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2021.119635_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1479164112460253","article-title":"Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients","volume":"10","author":"Kerkeni","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.lfs.2021.119635_bb0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc10-1087","article-title":"Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study","volume":"34","author":"Nin","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2016.08.022","article-title":"Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: an update","volume":"791","author":"Bhattacharjee","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119635_bb0125","series-title":"Aldose Reductase: New Insights for an Old Enzyme","author":"Ramana","year":"2011"},{"key":"10.1016\/j.lfs.2021.119635_bb0130","doi-asserted-by":"crossref","unstructured":"A.S. De Vriese, R.G. Tilton, M. ELGER, C.C. Stephan, W. KRIZ, N.H. Lameire, Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes, J. Am. Soc. Nephrol. 12 (2001) 993\u20131000.","DOI":"10.1681\/ASN.V125993"},{"key":"10.1016\/j.lfs.2021.119635_bb0135","doi-asserted-by":"crossref","first-page":"20309","DOI":"10.1074\/jbc.M202634200","article-title":"Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells","volume":"277","author":"Yamagishi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119635_bb0140","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2174\/1381612054367300","article-title":"Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy","volume":"11","author":"Yamagishi","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2021.119635_bb0145","unstructured":"H. Abe, Recent progress in understanding the molecular pathogenesis of diabetic nephropathy, Rinsho Byori. 59 (2011) 179\u2013186."},{"key":"10.1016\/j.lfs.2021.119635_bb0150","doi-asserted-by":"crossref","first-page":"H1675","DOI":"10.1152\/ajpheart.91493.2007","article-title":"Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production","volume":"294","author":"Singh","year":"2008","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"10.1016\/j.lfs.2021.119635_bb0155","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/bjp.2008.26","article-title":"Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway","volume":"153","author":"Zheng","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119635_bb0160","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jcm9020458","article-title":"Inflammatory targets in diabetic nephropathy","volume":"9","author":"Donate-Correa","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0165","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.2337\/diabetes.52.10.2586","article-title":"Intercellular adhesion molecule-1\u2013deficient mice are resistant against renal injury after induction of diabetes","volume":"52","author":"Okada","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2021.119635_bb0170","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1681\/ASN.V111152","article-title":"Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies","volume":"11","author":"Segerer","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0180","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1440-1797.2006.00576.x","article-title":"Macrophage accumulation in human progressive diabetic nephropathy","volume":"11","author":"Nguyen","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.lfs.2021.119635_bb0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0190","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1681\/ASN.2004110961","article-title":"Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes","volume":"16","author":"Dalla Vestra","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0195","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1002\/jcp.27427","article-title":"Interleukin-18 and diabetic nephropathy: a review","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lfs.2021.119635_bb0200","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1681\/ASN.2007050556","article-title":"Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics","volume":"19","author":"Wolkow","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0205","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2215\/CJN.03010608","article-title":"Serum concentrations of markers of TNF\u03b1 and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes","volume":"4","author":"Niewczas","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0210","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clinbiochem.2012.02.021","article-title":"Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy","volume":"45","author":"El Mesallamy","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.lfs.2021.119635_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1681\/ASN.V11125","article-title":"Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis","volume":"11","author":"Riser","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/diacare.29.01.06.dc05-1670","article-title":"Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy","volume":"29","author":"Nguyen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0225","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1681\/ASN.V12102098","article-title":"Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy","volume":"12","author":"Kelly","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/dmrr.1068","article-title":"Urinary biomarkers involved in type 2 diabetes: a review","volume":"26","author":"Matheson","year":"2010","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.lfs.2021.119635_bb0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ki.1997.310","article-title":"In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy","volume":"52","author":"Suzuki","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0240","doi-asserted-by":"crossref","unstructured":"M.A.K. Salem, S.A. El-Habashy, O.M. Saeid, M.M.K. El-Tawil, P.H. Tawfik, Urinary excretion of n-acetyl-\u03b2-d-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus, Pediatr. Diabetes 3 (2002) 37\u201341.","DOI":"10.1034\/j.1399-5448.2002.30107.x"},{"key":"10.1016\/j.lfs.2021.119635_bb0245","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2337\/diacare.26.2.338","article-title":"Urinary \u03b11-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore","volume":"26","author":"Hong","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0250","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.2010.404","article-title":"Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-\u03b2-d-glucosaminidase","volume":"79","author":"Vaidya","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1056-8727(00)00119-7","article-title":"Urinary protein excretion in type 2 diabetes with complications","volume":"14","author":"Hong","year":"2000","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.lfs.2021.119635_bb0260","doi-asserted-by":"crossref","unstructured":"J.A.M. De Carvalho, S.J. Piva, B.S. Hausen, G. V Bochi, M. Kaefer, A.C. Coelho, M.M.M.F. Duarte, R.N. Moresco, Assessment of urinary \u03b3-glutamyltransferase and alkaline phosphatase for diagnosis of diabetic nephropathy, Clin. Chim. Acta 412 (2011) 1407\u20131411.","DOI":"10.1016\/j.cca.2011.04.015"},{"key":"10.1016\/j.lfs.2021.119635_bb0265","first-page":"559","article-title":"Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients","volume":"18","author":"Uslu","year":"2005","journal-title":"J. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0270","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc09-0429","article-title":"Tubular and glomerular injury in diabetes and the impact of ACE inhibition","volume":"32","author":"Nielsen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0275","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1464-5491.2010.03083.x","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril","volume":"27","author":"Nielsen","year":"2010","journal-title":"Diabet. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0280","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12020-011-9509-7","article-title":"Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study","volume":"41","author":"Fu","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.lfs.2021.119635_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002921","article-title":"New susceptibility loci associated with kidney disease in type 1 diabetes","volume":"8","author":"Sandholm","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.lfs.2021.119635_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002150","article-title":"Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans","volume":"7","author":"Freedman","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.lfs.2021.119635_bb0295","doi-asserted-by":"crossref","unstructured":"N. Nazir, K. Siddiqui, S. Al-Qasim, D. Al-Naqeb, Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways, BMC Med. Genet. 15 (2014) 1\u201314.","DOI":"10.1186\/s12881-014-0103-8"},{"key":"10.1016\/j.lfs.2021.119635_bb0300","doi-asserted-by":"crossref","unstructured":"A. El-Osta, D. Brasacchio, D. Yao, A. Pocai, P.L. Jones, R.G. Roeder, M.E. Cooper, M. Brownlee, Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia, J. Exp. Med. 205 (2008) 2409\u20132417.","DOI":"10.1084\/jem.20081188"},{"key":"10.1016\/j.lfs.2021.119635_bb0305","doi-asserted-by":"crossref","unstructured":"E. Zhang, Y. Wu, Metabolic memory: mechanisms and implications for diabetic vasculopathies., Sci. China Life Sci. 57 (2014) 845\u2013851. doi:https:\/\/doi.org\/10.1007\/s11427-014-4710-6.","DOI":"10.1007\/s11427-014-4710-6"},{"key":"10.1016\/j.lfs.2021.119635_bb0310","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/dc06-2056","article-title":"Proteomic identification of urinary biomarkers of diabetic nephropathy","volume":"30","author":"Rao","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0315","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/jcm7120483","article-title":"Urinary proteomics for the early diagnosis of diabetic nephropathy in Taiwanese patients","volume":"7","author":"Liao","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0320","doi-asserted-by":"crossref","unstructured":"M.E. Cooper, Pathogenesis, prevention, and treatment of diabetic nephropathy., Lancet (London, England). 352 (1998) 213\u2013219. doi:https:\/\/doi.org\/10.1016\/S0140-6736(98)01346-4.","DOI":"10.1016\/S0140-6736(98)01346-4"},{"key":"10.1016\/j.lfs.2021.119635_bb0325","doi-asserted-by":"crossref","unstructured":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. The Diabetes Control and Complications (DCCT) Research Group., Kidney Int. 47 (1995) 1703\u20131720. doi:https:\/\/doi.org\/10.1038\/ki.1995.236.","DOI":"10.1038\/ki.1995.236"},{"key":"10.1016\/j.lfs.2021.119635_bb0330","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/dom.12630","article-title":"Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?","volume":"18","author":"Gallagher","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2021.119635_bb0335","unstructured":"O.E. Ayodele, C.O. Alebiosu, B.L. Salako, Diabetic nephropathy\u2013a review of the natural history, burden, risk factors and treatment., J. Natl. Med. Assoc.. 96 (2004) 1445\u20131454."},{"key":"10.1016\/j.lfs.2021.119635_bb0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.jhh.1001444","article-title":"Rosiglitazone reduces urinary albumin excretion in type II diabetes","volume":"17","author":"Bakris","year":"2003","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.lfs.2021.119635_bb0345","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.lfs.2021.119635_bb0350","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2337\/diacare.27.8.1897","article-title":"Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patie","volume":"27","author":"Palmer","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0355","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0360","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0365","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0370","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0375","unstructured":"S. Sen, B. Ufuktepe, Z.G. \u00d6z\u00fcnal, Y. \u00dcresin, Renin inhibitors in diabetes and hypertension: an update., EXCLI J.. 13 (2014) 1111\u20131119."},{"key":"10.1016\/j.lfs.2021.119635_bb0380","doi-asserted-by":"crossref","unstructured":"J. Ahmad, Management of diabetic nephropathy: recent progress and future perspective., Diabetes Metab. Syndr. 9 (2015) 343\u2013358. doi:https:\/\/doi.org\/10.1016\/j.dsx.2015.02.008.","DOI":"10.1016\/j.dsx.2015.02.008"},{"key":"10.1016\/j.lfs.2021.119635_bb0385","doi-asserted-by":"crossref","unstructured":"S.M. Grundy, J.I. Cleeman, C.N.B. Merz, H.B.J. Brewer, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C.J. Smith, N.J. Stone, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines., J. Am. Coll. Cardiol. 44 (2004) 720\u2013732. doi:https:\/\/doi.org\/10.1016\/j.jacc.2004.07.001.","DOI":"10.1016\/j.jacc.2004.07.001"},{"key":"10.1016\/j.lfs.2021.119635_bb0390","doi-asserted-by":"crossref","unstructured":"G. Bruno, F. Merletti, A. Biggeri, G. Bargero, S. Ferrero, G. Pagano, P. Cavallo Perin, Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato study., Diabetes Care. 26 (2003) 2150\u20132155. doi:https:\/\/doi.org\/10.2337\/diacare.26.7.2150.","DOI":"10.2337\/diacare.26.7.2150"},{"key":"10.1016\/j.lfs.2021.119635_bb0395","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1523-1755.2001.00487.x","article-title":"Effect of lipid reduction on the progression of renal disease: a meta-analysis","volume":"59","author":"Fried","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0400","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.metabol.2012.01.006","article-title":"Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level","volume":"61","author":"Ishibashi","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2021.119635_bb0405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5301\/jn.5000128","article-title":"Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells","volume":"26","author":"Gao","year":"2013","journal-title":"J. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0410","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1440-1681.2010.05436.x","article-title":"Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes","volume":"37","author":"Toba","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.lfs.2021.119635_bb0415","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.5551\/jat.9084","article-title":"Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy","volume":"18","author":"Abe","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.lfs.2021.119635_bb0420","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.ki.5001515","article-title":"Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes","volume":"70","author":"Tonolo","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0425","doi-asserted-by":"crossref","unstructured":"H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A.W. Neil, S.J. Livingstone, V. Charlton-Menys, D.A. DeMicco, J.H. Fuller, C. Investigators, Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS), Am. J. Kidney Dis. 54 (2009) 810\u2013819.","DOI":"10.1053\/j.ajkd.2009.03.022"},{"key":"10.1016\/j.lfs.2021.119635_bb0430","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000046648","article-title":"Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia","volume":"21","author":"Nakamura","year":"2001","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0435","doi-asserted-by":"crossref","unstructured":"K. Endo, Y. Miyashita, H. Sasaki, M. Ohira, A. Saiki, N. Koide, M. Otsuka, T. Oyama, M. Takeyoshi, Y. Ito, Probucol delays progression of diabetic nephropathy, Diabetes Res. Clin. Pract. 71 (2006) 156\u2013163.","DOI":"10.1016\/j.diabres.2005.05.012"},{"key":"10.1016\/j.lfs.2021.119635_bb0440","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"G\u00e6de","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0445","doi-asserted-by":"crossref","unstructured":"C.B.T. Makura, K. Nirantharakumar, A.J. Girling, P. Saravanan, P. Narendran, Effects of physical activity on the development and progression of microvascular complications in type 1 diabetes: retrospective analysis of the DCCT study, BMC Endocr. Disord. 13 (2013) 1\u20136.","DOI":"10.1186\/1472-6823-13-37"},{"key":"10.1016\/j.lfs.2021.119635_bb0450","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0455","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2337\/diacare.27.6.1454","article-title":"Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study","volume":"27","author":"A.D. Association","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2021.119635_bb0460","first-page":"S14","article-title":"Standards of medical care in diabetes--2014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0465","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2337\/diacare.25.4.645","article-title":"Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial","volume":"25","author":"Gross","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0470","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002934","article-title":"Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials","volume":"3","author":"Nezu","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.lfs.2021.119635_bb0475","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/diacare.25.4.663","article-title":"A low-sodium diet potentiates the effects of losartan in type 2 diabetes","volume":"25","author":"Houlihan","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0480","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2021.119635_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2020.108451","article-title":"Nrf2 participates in the anti-apoptotic role of zinc in type 2 diabetic nephropathy through Wnt\/\u03b2-catenin signaling pathway","volume":"84","author":"Wang","year":"2020","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.lfs.2021.119635_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119197","article-title":"Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-\u03b2\/Smad and JAK2\/STAT3\/SOCS1 pathway","volume":"271","author":"Chen","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2021.119635_bb0495","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/mnfr.201100080","article-title":"Curcumin attenuates diabetic nephropathy by inhibiting PKC-\u03b1 and PKC-\u03b21 activity in streptozotocin-induced type I diabetic rats","volume":"55","author":"Soetikno","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.lfs.2021.119635_bb0500","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.drudis.2013.04.009","article-title":"Molecular understanding of curcumin in diabetic nephropathy","volume":"18","author":"Soetikno","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2021.119635_bb0505","doi-asserted-by":"crossref","unstructured":"D. Hayashi, L. Wang, S. Ueda, M. Yamanoue, H. Ashida, Y. Shirai, The mechanisms of ameliorating effect of a green tea polyphenol on diabetic nephropathy based on diacylglycerol kinase \u03b1., Sci. Rep. 10 (2020) 11790. doi:https:\/\/doi.org\/10.1038\/s41598-020-68716-6.","DOI":"10.1038\/s41598-020-68716-6"},{"key":"10.1016\/j.lfs.2021.119635_bb0510","doi-asserted-by":"crossref","unstructured":"L.C.M. Ladeira, E.C. Dos Santos, T.A. Santos, J. da Silva, G.D. de A. Lima, M. Machado-Neves, R.C. da Silva, M.B. Freitas, I.R.D.S.C. Maldonado, Green tea infusion prevents diabetic nephropathy aggravation in recent-onset type 1 diabetes regardless of glycemic control., J. Ethnopharmacol. 274 (2021) 114032. doi:https:\/\/doi.org\/10.1016\/j.jep.2021.114032.","DOI":"10.1016\/j.jep.2021.114032"},{"key":"10.1016\/j.lfs.2021.119635_bb0515","first-page":"e21559","article-title":"Fish oil replacement prevents, while docosahexaenoic acid-derived protectin DX mitigates end-stage-renal-disease in atherosclerotic diabetic mice","volume":"35","author":"Perazza","year":"2021","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.lfs.2021.119635_bb0520","doi-asserted-by":"crossref","unstructured":"J. Cederholm, B. Eliasson, P.M. Nilsson, L. Weiss, S. Gudbj\u00f6rnsdottir, Microalbuminuria and risk factors in type 1 and type 2 diabetic patients., Diabetes Res. Clin. Pract. 67 (2005) 258\u2013266. doi:https:\/\/doi.org\/10.1016\/j.diabres.2004.07.021.","DOI":"10.1016\/j.diabres.2004.07.021"},{"key":"10.1016\/j.lfs.2021.119635_bb0525","unstructured":"G. Gambaro, G. Bax, M. Fusaro, M. Normanno, S.M. Manani, M. Zanella, A. Dangelo, D. Fedele, S. Favaro, Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus., Diabetes Nutr. Metab. 14 (2001) 337\u2013342."},{"key":"10.1016\/j.lfs.2021.119635_bb0530","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s11255-017-1638-3","article-title":"Smoking as a risk factor for diabetic nephropathy: a meta-analysis","volume":"49","author":"Su","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0535","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00592-015-0822-0","article-title":"Smoking and progression of diabetic nephropathy in patients with type 1 diabetes","volume":"53","author":"Feodoroff","year":"2016","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.lfs.2021.119635_bb0540","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/jcm4061171","article-title":"Endothelin blockade in diabetic kidney disease","volume":"4","author":"Anguiano","year":"2015","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2021.119635_bb0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin a receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0550","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.lfs.2021.119635_bb0555","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0560","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0565","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0570","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.lfs.2021.119635_bb0575","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1021\/jm050462t","article-title":"A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners","volume":"48","author":"Mylari","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.lfs.2021.119635_bb0580","doi-asserted-by":"crossref","unstructured":"I. Itagaki, K. Shimizu, Y. Kamanaka, K. Ebata, R. Kikkawa, M. Haneda, Y. Shigeta, The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats., Diabetes Res. Clin. Pract. 25 (1994) 147\u2013154. doi:https:\/\/doi.org\/10.1016\/0168-8227(94)90002-7.","DOI":"10.1016\/0168-8227(94)90002-7"},{"key":"10.1016\/j.lfs.2021.119635_bb0585","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1056-8727(01)00160-X","article-title":"Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patients","volume":"15","author":"Iso","year":"2001","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.lfs.2021.119635_bb0590","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/dc05-2370","article-title":"Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial","volume":"29","author":"Hotta","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0595","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","article-title":"Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy","volume":"28","author":"Ramirez","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.lfs.2021.119635_bb0600","doi-asserted-by":"crossref","unstructured":"M. Chatzopoulou, P. Alexiou, E. Kotsampasakou, V.J. Demopoulos, Novel aldose reductase inhibitors: a patent survey (2006\u2013present)., Expert Opin. Ther. Pat. 22 (2012) 1303\u20131323. doi:https:\/\/doi.org\/10.1517\/13543776.2012.726615.","DOI":"10.1517\/13543776.2012.726615"},{"key":"10.1016\/j.lfs.2021.119635_bb0605","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1523-1755.2004.00367.x","article-title":"Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury","volume":"65","author":"Chow","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2021.119635_bb0610","first-page":"307","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc."},{"key":"10.1016\/j.lfs.2021.119635_bb0615","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2021.119635_bb0620","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1681\/ASN.2010020218","article-title":"NF-kappaB in renal inflammation","volume":"21","author":"Sanz","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0625","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000327599","article-title":"Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD","volume":"33","author":"Pergola","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0630","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/147323000903700117","article-title":"The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozotocin-induced diabetic rats","volume":"37","author":"Wang","year":"2009","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.lfs.2021.119635_bb0635","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.metabol.2004.06.005","article-title":"Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka long-Evans Tokushima fatty rat","volume":"53","author":"Tohma","year":"2004","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2021.119635_bb0640","doi-asserted-by":"crossref","unstructured":"X.-M. Jiao, X.-J. Jiao, X.-G. Zhang, X.-P. Xu, J.-X. Wu, L. Yao, J. Zhao, X.-F. L\u00fc, Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy., Chin. Med. J. 126 (2013) 4395\u20134396.","DOI":"10.3760\/cma.j.issn.0366-6999.20131503"},{"key":"10.1016\/j.lfs.2021.119635_bb0645","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/08860221003602645","article-title":"Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy","volume":"32","author":"Roozbeh","year":"2010","journal-title":"Ren. Fail."},{"key":"10.1016\/j.lfs.2021.119635_bb0650","unstructured":"F. Oliaei, S. Hushmand, S. Khafri, M. Baradaran, Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients., Casp. J. Intern. Med. 2 (2011) 309\u2013313."},{"key":"10.1016\/j.lfs.2021.119635_bb0655","doi-asserted-by":"crossref","unstructured":"M.S. Farvid, F. Homayouni, Z. Amiri, F. Adelmanesh, Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation., Diabetes Res. Clin. Pract. 93 (2011) 86\u201394. doi:https:\/\/doi.org\/10.1016\/j.diabres.2011.03.016.","DOI":"10.1016\/j.diabres.2011.03.016"},{"key":"10.1016\/j.lfs.2021.119635_bb0660","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.2337\/diacare.28.10.2458","article-title":"Comparison of the effects of vitamins and\/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes","volume":"28","author":"Farvid","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119635_bb0665","doi-asserted-by":"crossref","unstructured":"S. Golbidi, S.A. Ebadi, I. Laher, Antioxidants in the treatment of diabetes., Curr. Diabetes Rev. 7 (2011) 106\u2013125. doi:https:\/\/doi.org\/10.2174\/157339911794940729.","DOI":"10.2174\/157339911794940729"},{"key":"10.1016\/j.lfs.2021.119635_bb0670","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2021.119635_bb0675","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00125-003-1205-6","article-title":"Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment","volume":"46","author":"Etoh","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2021.119635_bb0680","doi-asserted-by":"crossref","first-page":"F1348","DOI":"10.1152\/ajprenal.00028.2010","article-title":"Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy","volume":"299","author":"Sedeek","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.lfs.2021.119635_bb0685","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1681\/ASN.2013070810","article-title":"Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy","volume":"25","author":"Jha","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0690","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2337\/db16-1585","article-title":"NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy","volume":"66","author":"Jha","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2021.119635_bb0695","doi-asserted-by":"crossref","unstructured":"M. Ciszewicz, A. PoLubinska, A. Antoniewicz, K. Suminska-Jasinska, A. Br\u0118borowicz, Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity, Transl. Res. 153 (2009) 118\u2013123.","DOI":"10.1016\/j.trsl.2008.12.007"},{"key":"10.1016\/j.lfs.2021.119635_bb0700","doi-asserted-by":"crossref","unstructured":"V. Masola, G. Zaza, G. Gambaro, Sulodexide and glycosaminoglycans in the progression of renal disease, Nephrol. Dial. Transplant. 29 (2014) i74\u2013i79.","DOI":"10.1093\/ndt\/gft389"},{"key":"10.1016\/j.lfs.2021.119635_bb0705","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.ASN.0000014254.87188.E5","article-title":"Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. NAS randomized trial","volume":"13","author":"Gambaro","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0710","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.abb.2003.08.013","article-title":"Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts","volume":"419","author":"Thornalley","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.lfs.2021.119635_bb0715","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.lfs.2021.119635_bb0720","doi-asserted-by":"crossref","unstructured":"L. Kennedy, M.P. Solano, L. Meneghini, M. Lo, M.P. Cohen, Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes, Am. J. Nephrol. 31 (2010) 110\u2013116.","DOI":"10.1159\/000259897"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521006214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521006214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:39:47Z","timestamp":1731573587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521006214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":144,"alternative-id":["S0024320521006214"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119635","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic nephropathy: A twisted thread to unravel","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119635"}}